

## PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1  
 Stylesheet Version v1.2

EPAS ID: PAT6932120

<b>SUBMISSION TYPE:</b>	NEW ASSIGNMENT
<b>NATURE OF CONVEYANCE:</b>	ASSIGNMENT
<b>CONVEYING PARTY DATA</b>	
<b>Name</b>	<b>Execution Date</b>
AVINASH P. PHADKE	04/29/2020
AKIHIRO HASHIMOTO	04/23/2020
<b>RECEIVING PARTY DATA</b>	
<b>Name:</b>	ACHILLION PHARMACEUTICALS, INC.
<b>Street Address:</b>	121 SEAPORT BLVD.
<b>City:</b>	BOSTON
<b>State/Country:</b>	MASSACHUSETTS
<b>Postal Code:</b>	02210
<b>PROPERTY NUMBERS Total: 1</b>	
<b>Property Type</b>	<b>Number</b>
<b>Application Number:</b>	17279767
<b>CORRESPONDENCE DATA</b>	
<b>Fax Number:</b>	(617)428-7045
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>	
<b>Phone:</b>	(617) 428-0200
<b>Email:</b>	patentadmin@clarkelbing.com
<b>Correspondent Name:</b>	CLARK & ELBING LLP
<b>Address Line 1:</b>	101 FEDERAL STREET
<b>Address Line 2:</b>	15TH FLOOR
<b>Address Line 4:</b>	BOSTON, MASSACHUSETTS 02110
<b>ATTORNEY DOCKET NUMBER:</b>	51505-036005
<b>NAME OF SUBMITTER:</b>	JEFFREY J. ELLISON, PH.D.
<b>SIGNATURE:</b>	/Jeffrey J. Ellison, Ph.D./
<b>DATE SIGNED:</b>	09/22/2021
<b>Total Attachments: 4</b>	
source=51505-036WO5 Executed Assignment - Phadke and Hashimoto#page1.tif	
source=51505-036WO5 Executed Assignment - Phadke and Hashimoto#page2.tif	
source=51505-036WO5 Executed Assignment - Phadke and Hashimoto#page3.tif	
source=51505-036WO5 Executed Assignment - Phadke and Hashimoto#page4.tif	

---

ASSIGNMENT

---

WHEREAS, We, **AVINASH P. PHADKE** of Branford, CT and **AKIHIRO HASHIMOTO** of Branford, CT (“**ASSIGNORS**”), have invented certain new and useful inventions and improvements disclosed in PCT Patent Application titled “**MORPHIC FORMS OF COMPLEMENT FACTOR D INHIBITORS**,” filed in the United States Patent and Trademark Office acting as the Receiving Office on **September 25, 2019**, and assigned PCT Application No. **PCT/US19/53012** (“**PCT Application**”), which claims priority to U.S. provisional patent applications titled “**MORPHIC FORMS OF COMPLEMENT FACTOR D-INHIBITORS**,” which is identified in the United States Patent and Trademark Office by Provisional Application No. **62/736,294** filed on **September 25, 2018**; Provisional Application No. **62/757,565** filed on **November 8, 2018**; Provisional Application No. **62/760,520** filed on **November 13, 2018**; and Provisional Application No. **62/796,776** filed **January 25, 2019**, and for which an application for Letters Patent in the United States and/or other foreign jurisdictions claiming priority to the PCT Application will be made..

WHEREAS, **ACHILLION PHARMACEUTICALS, INC.** (“**ASSIGNEE**”), a business entity organized and existing under the laws of the state of Delaware, and having its principal offices at 1777 Sentry Parkway West, VEVA Building #14, Blue Bell, PA 19422, is entitled to the ownership of these inventions and improvements and all applications describing these inventions and improvements by virtue of the employment of the inventors and/or a contractual agreement, and thus desires to acquire, or to the extent already done so then to confirm the acquisition of, the entire right, title, and interest in and to said inventions, improvements, know-how, and the PCT Application and in and to the Letters Patents which may be granted therefrom.

NOW, THEREFORE, for good and valuable consideration previously received, the receipt and sufficiency of which is hereby acknowledged, **ASSIGNORS** by these presents do sell, assign, and transfer, or to the extent already done so then confirm the sale, assignment, and transfer, to **ASSIGNEE** the full, exclusive, and entire right, title, and interest in and to all inventions and improvements disclosed and described in said PCT Application, as well as all know-how derived during the development of, and directed to, the inventions and improvements disclosed and described in said PCT Application.

For the same consideration, **ASSIGNORS**, by these presents, do sell, assign, and transfer, or to the extent already done so then confirm the sale, assignment, and transfer, to **ASSIGNEE**, the full, exclusive, and entire right, title, and interest in and to any U.S. nonprovisional or foreign application or any other applications that correspond to or claim priority to said PCT Application, in whole or in part, and to any Letters Patents and similar protective rights granted on said U.S. nonprovisional or foreign applications,

and in and to the right to claim any applicable priority rights arising from or required for said U.S. nonprovisional or foreign applications under the terms of any applicable conventions, treaties, statutes, or regulations, including to all divisions, continuations, continuations-in-part, or renewals thereof, all Letters Patents which may be granted therefrom, all reexaminations, and all reissues or extensions of such patents; said U.S. nonprovisional or foreign applications to be filed and issued in the name of ASSIGNEE or its designee insofar as permitted by applicable law;

AND, for the consideration aforesaid, ASSIGNORS do hereby agree, or to the extent already done so then confirm their agreement, that they or their executor(s) and legal representatives will make, execute and deliver any and all other instruments in writing including any and all further application papers, affidavits, assignments and other documents, and will communicate to said ASSIGNEE, its successors and representatives all facts known to ASSIGNORS relating to said inventions and improvements and the history thereof and will testify in all legal proceedings and generally do all things which may be necessary or desirable more effectually to secure to and vest in said ASSIGNEE, its successors or assigns the entire right, title, and interest in and to the said improvements, inventions, know how, applications, Letters Patents, rights, titles, benefits, privileges and advantages hereby assigned and conveyed, or intended so to be.

AND, furthermore, ASSIGNORS covenant and agree, or to the extent already done so then confirm their covenant and agreement with, said ASSIGNEE, its successors and assigns, that no assignment, grant, mortgage, license or other agreement affecting the rights and property herein conveyed has been made to others by ASSIGNORS and that full right to convey the same as herein expressed is possessed by ASSIGNORS.

The ASSIGNORS agree that this assignment is effective from the 25<sup>th</sup> day of September 2019.

4/29/2020  
Date

Ashadke  
Avinash P. Phadke

Witness:

4-29-2020  
Date

Jane Thomas  
Witness Name:

Apr. 23. 2020  
Date

A. Hashimoto  
Akirhiro Hashimoto

Witness:

Apr. 23. 2020  
Date

[Signature]  
Witness Name: